|Chemical and physical data|
|Molar mass||176.212 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Centalun was developed by Boehringer Ingelheim in 1962 and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABAA receptor. It was previously used for sedation in medical procedures such as surgery, orthopedics and gynecology, although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.
- BE Patent 618130
- Janke, W.; Glathe, H. (1964). "Experimental Studies on the Psychic Effect of Sedatives Under Normal and Stress Conditions". Psychologische Forschung. 27: 377–402. PMID 14233519.
- Monecke, K. (1964). "Pre- and Postoperative Use of Centalun in Surgery". Deutsches medizinisches Journal. 15: 470–471. PMID 14238754.
- Bruckschen, E. (1964). "Sedative Therapy with Centalun in Orthopedics". Deutsches medizinisches Journal. 15: 493–494. PMID 14243120.
- Gerlach, W.; Gerlach, E. (1964). "Experiences with Centalun in Obstetrical and Gynecological Patients". Medizinische Monatsschrift. 18: 131–133. PMID 14193290.